Shares of China's Landsea Green rise on plan to buy Texas homebuilder for $185 million
By Kimberley Kao
Shares of Chinese developer Landsea Green Management (HK:106) rose after the company said its Nasdaq-listed unit will buy a Texas homebuilder for $185 million.
Shares were up 19% in early Hong Kong trading Friday, lifting the stock into the green for the year.
Landsea Green said ahead of trading that its Landsea Homes subsidiary (LSEA) plans to acquire Texas-based family homebuilder Antares Acquisition, subject to shareholder approval. It plans to pay a base purchase price of $185 million, funded by Landsea Homes' internal resources.
Landsea Green, which has property operations in the U.S. and China, said the deal will help it expand into the Dallas/Fort Worth area.
Landsea Green holds a 54% stake in Landsea Homes. Shares of the U.S. unit are up 87% over the past 12 months.
The news follows Landsea Homes' announcement last month that it is expanding in Arizona with 145 new homesites.
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
02-01-24 2234ET
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks